Updated:
Inogen
Inogen: Kevin Smith runs the portable oxygen concentrator maker that sells directly to respiratory patients, bypassing legacy DME distributors.
Inogen
Founded in 2001 in Goleta, California, Inogen commercialized a lightweight portable oxygen concentrator that freed chronic obstructive pulmonary disease patients from stationary tanks. The company listed on Nasdaq in 2014 and built its distribution around direct consumer sales and partnerships with home medical equipment providers rather than the prescription intermediary model dominant among legacy oxygen suppliers. Inogen sells portable and stationary oxygen concentrators across North America and Europe. The product line targets the homecare respiratory market — a segment historically controlled by durable medical equipment reimbursement codes. Inogen competes against ResMed's mobility segment, CAIRE Inc., and Philips' legacy oxygen business. Unlike traditional oxygen providers that rely on rental billing models, Inogen captures margin through upfront device sales, direct-to-consumer e-commerce, and a network of respiratory therapists who prescribe the device outside the hospital discharge pathway. The company operates a manufacturing facility in Plano, Texas, and an assembly plant in the Netherlands. Kevin Smith joined as CEO in 2017 after leadership roles at Baxter and Allegiance Healthcare. The firm has historically reported quarterly revenue tracked alongside Medicare reimbursement rate adjustments and home oxygen patient volume trends — two variables that govern the addressable market. Inogen's structure as a listed medical device manufacturer operating a cash-pay sales channel distinguishes it from durable medical equipment providers that bill third-party payors. The direct-to-patient model gives the company pricing control and customer acquisition data that traditional oxygen providers lack — though it also exposes the top line to consumer discretionary spending sensitivity in a product category where rental remains the default for most Medicare beneficiaries. (per public record, 2024)
General information
Firm type
Asset Manager
Year founded
2001
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Goleta
Corporate office
Goleta, CA, United States
Principals
Kevin Smith
President and Chief Executive Officer
Sector focus
Frequently asked questions
Does Inogen sell directly to patients or through insurance reimbursement?
Inogen sells portable oxygen concentrators directly to patients via e-commerce and a network of respiratory therapists, capturing revenue at the point of sale rather than through recurring rental billing to Medicare or private insurers. The direct-to-consumer model gives the company pricing control outside the durable medical equipment reimbursement codes that govern legacy oxygen suppliers.
Who runs the company and what is their relevant background?
Kevin Smith joined Inogen as President and CEO in 2017. He previously held leadership roles at Baxter International and Allegiance Healthcare, bringing supply-chain and medical-device commercial experience to the firm's direct-to-patient distribution strategy.
What differentiates Inogen's market approach from traditional oxygen providers?
Legacy home oxygen providers rely on rental billing models tied to Medicare reimbursement, delivering stationary concentrators and refillable tanks through local distributors. Inogen sells portable, battery-operated units directly to patients — bypassing the prescription intermediary model and capturing full device margin upfront.
Where does Inogen manufacture its devices?
Inogen operates a manufacturing facility in Plano, Texas, and maintains an assembly plant in the Netherlands to serve its European distribution network. The firm sources components globally but performs final assembly and quality control at these owned facilities.
What geographic markets does Inogen serve?
Inogen's primary markets are North America and Europe, with sales concentrated in the United States. International revenue derives from direct sales in countries where the firm has established local distribution partnerships and regulatory clearances for its concentrator devices.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: